R. Dicecca

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

Lauren L. Ritterhouse, G. Getz, S. Digumarthy, 2016 .

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.

Lauren L. Ritterhouse, G. Getz, S. Digumarthy, 2016, Cancer discovery.

SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors

M. Lawrence, G. Caponigro, J. Engelman, 2018, Nature Medicine.

Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care

L. Sequist, A. Dastur, J. Engelman, 2017, Cell reports.

Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.

S. Digumarthy, A. Iafrate, M. Mino‐Kenudson, 2015, Cancer discovery.

ALK Resistance Mutations in ALK-Positive Lung Cancer

Lauren L. Ritterhouse, S. Digumarthy, A. Iafrate, 2016 .